Nereus Pharmaceuticals Raises $45M

San Diego-based Nereus Pharmaceuticals said Thursday that it has raised $45M in a Series D-2 financing. The new round of funding for the biopharmaceuticals firm was led by BankInvest Biomedical Venture of Copenhagen, and also included Roche Venture Fund, Astellas Venture Management, Boston Life Science Venture Corporation, Taiwan Global Biofund and Eminent Venture Capital Corporation. Existing investors in the round included HBM BioVentures, Alta Partners, Forward Ventures, Advent International, GIMV, InterWest Partners and Pacific Venture Group. Nereus is developing cancer therapeutics based on marine microbes. The firm said the funding will be drawn down in two tranches, and will be used for completing Phase I and beginning Phase II trials for two of its drug candidates. More information »